The FDA has approved a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA, with the cholesterol-lowering medication ZOCOR (simvastatin). The new drug, produced by Merck, known as MSD outside the United States and Canada, will be… Read more
New data presented at the European Association for the Study of Diabetes (EASD) shows a significantly higher proportion of patients reached target HbA1c levels of <7% when Victoza (liraglutide [rDNA origin] injection) was administrated early in the treatment of type 2 diabetes to patients who had not received treatment before or had previously received only one oral anti-diabetic drug (OAD)... Read more
New data from two extension studies presented by Novo Nordisk at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) show that Victoza (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies Byetta (exenatide) and Januvia (sitagliptin). Although not.. Read more
New Patient Reported Outcomes (PRO) data presented by today at the European Association for the Study of Diabetes (EASD) congress in Stockholm challenge the widespread perception that patients prefer oral to injected glucose-lowering therapies.
Results from the 26-week, open-label study show that patients taking injectable Victoza (liraglutide 1.8 mg) reported significantly higher overall treatment satisfaction after 26 weeks than… Read more
Incretin-based treatments target the beta cell and enhance the release of insulin based on the amount of glucose in the blood… Read more
Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia plus metformin at 52 weeks… Read more
Novo Nordisk’s new diabetes drug Victoza proved more effective than Merck & Co’s Januvia in a head-to-head study published, in the Lancet.
The 26-week trial showed that Victoza produced significantly greater reductions in HbA1C, fasting plasma glucose and body weight than Januvia, with similar or better overall treatment satisfaction…. Read more
The Swiss -based pharmaceuticals and diagnostics company Roche Holding AG announced headline results from the second and third of eight T-emerge Phase III studies for taspoglutide.
Taspoglutide is the first once-weekly human glucagon-like peptide-1 (GLP-1) analogue being developed to address the important unmet needs of patients with type 2 diabetes…. Read more
According to Diabetes UK the European Commission has approved Sitagliptin ,known as Januvia, as an add-on to insulin (with or without metformin) for people with type 2 diabetes. Most type 2 diabetics can control their condition with a combination of diet, physical activity and conventional medication. Januvia was approved by the FDA in 2006… Read more